Cholestasis gravidarum in women in the second and third trimester of gestation, clinical and specific pharmacological treatment and its benefits. An evidence-based approach

Lorran Nobre Da Silva; Marcelo Adrian Estrin

doi:10.56294/dm202276

Systematic reviews or meta-analyses

Published: 2022-12-02

DOI: https://doi.org/10.56294/dm202276

Cholestasis gravidarum in women in the second and third trimester of gestation, clinical and specific pharmacological treatment and its benefits. An evidence-based approach

Abstract

Introduction: Cholestasis gravidarum is a syndrome that usually occurs in pregnant women in the second or third trimester of gestation and ends in the puerperium. It is clinically characterized by the presence of predominantly nocturnal pruritus that is initially palmo-plantar and then generalized. With alterations in liver function with or without jaundice and elevated serum bile acid levels, biochemical cholestasis is classified as mild to moderate severity.
Objective: Diagnostic methods and pharmacological treatment approaches that provide the best results for these patients.
Methods: Systematic review using the terms MESH (cholestasis of pregnancy) that generated 2597 results.
Results: 28 papers were analyzed in more detail, of which 12 papers were finally selected for the final analysis. Treatment: Ursodeoxycholic acid (UDCA), a beta epimer of chenodeoxycholic acid, is a bile acid more polar than primary bile acids, with substantial choleretic and other multiple chemoprotective effects. The mechanism of action is not completely understood, but studies have shown that after treatment there is a reduction in total serum bile acids in both maternal and cord serum and a qualitative change in the serum bile acid pool. When compared with all controls, UDCA was also found to be associated with a decrease in the incidence of preterm birth, neonatal respiratory distress, and the number of neonatal admissions to intensive care units.
Conclusions: The treatment of cholestasis gravidarum is oral administration of ursodeoxycholic acid is effective and safe in the treatment of patients with cholestasis gravidarum.

Keywords:

Pruritus,

Jaundice,

Fetal Distress,

Evidence-based Decisions,

How to Cite

Nobre Da Silva L, Estrin MA. Cholestasis gravidarum in women in the second and third trimester of gestation, clinical and specific pharmacological treatment and its benefits. An evidence-based approach. Data and Metadata [Internet]. 2022 Dec. 2 [cited 2024 Jul. 6];1:38. Available from: https://dm.saludcyt.ar/index.php/dm/article/view/76

Copyright Notice

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

Vol. 1 (2022)

See full issue

Revistas / Journals

Issue

About

Submissions

Cholestasis gravidarum in women in the second and third trimester of gestation, clinical and specific pharmacological treatment and its benefits. An evidence-based approach

Abstract

Keywords:

How to Cite

Copyright Notice

Article metrics

Metrics

Vol. 1 (2022)

Disclaimer